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ABSTRACT
A simple, precise, accurate, rapid and sensitive reverse –phase High Performance 
Liquid Chromatography method for the estimation of Escitalopram oxalate in human 
plasma was developed and validated. Sample preparation was carried out using solid 
phase extraction (SPE) method. The separation of Escitalopram in biological fluid
with the internal standard Tinidazole was achieved by Enable C18 column using 0.2% 
ortho phosphoric acid and acetonitrile in the ratio of 65:35%v/v  as mobile phase at a 
flow rate of 1.0ml/min at ambient temperature. Detection was carried out at 240nm.
The retention time of internal standard and Escitalopram was found to be 4.7 and 
10.5 min respectively. The standard curve was linear (R2 >0.995) over the
concentration range of 100-800 ng/ml. All the analytical validation parameters were 
determined as per ICH guidelines. The bioanalytical method developed was
selective, robust and reliable as accuracy, precision, recovery and other validation 
parameters were within the limits as specified by the guidelines. The peaks obtained 
for the drug of interest and internal standard were well resolved from each other 
without any plasma interferences and the peaks were symmetrical in nature with 
acceptable tailing factor. The method can be very useful for the therapeutic drug 
monitoring (TDM), in bioequivalence studies, for pharmacokinetics study and also 
in toxicology and biomedical investigations.
Key words: RP-HPLC, Escitalopram oxalate, Solid phase extraction, Human plasma
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INTRODUCTION
BIOANALYSIS [1-3]
Bioanalysis is the method used to determine the concentration of drugs, their 
metabolites and / or endogenous substances in the biological matrices such as blood plasma, 
serum, cerebrospinal fluid, urine and saliva. Bioanalytical methods are widely used to 
quantitative drugs and their metabolites in the physiological matrices and the methods could be 
applied to studies in areas of human clinical pharmacology and non human pharmacology / 
toxicology. Bioanalytical method employed for the quantitative determination of drugs and their 
metabolites in biological fluids plays a significant role in the evaluation and interpretation of 
bioequivalence, pharmacokinetics and toxic kinetic studies. It helps in carrying studies like 
pharmacodynamics, toxicology, pharmacokinetics, bioequivalence, therapeutic drug monitoring 
(TDM) and clinical studies.  Initial stages these studies are done only to find out over dosage 
conditions and in toxicological studies. When concentration of drug in biological matrix is 
known, then pharmacokinetic parameters are calculated from that. Bioanalytical studies are 
important in drug discovery and development. So these studies are performed carefully.
Therapeutic efficacy of the particular drug can be known by bioanalysis. In pharma field 
bioanalysis plays a significant role .Bioanalysis involves the following steps.
v Selection and collection of biological fluid.
v Preparation of sample –Analyte extraction from biological matrix.
v Analyte detection done by various methods.
ANALYSIS OF DRUG IN VARIOUS BIOLOGICAL MEDIA [4, 5]
The most common samples obtained for biopharmaceutical analysis are blood, urine, and 
feces, especially if the drug or metabolite is poorly absorbed or extensively excreted in the bile. 
Other media that can be utilized includes saliva, breath and tissue.
The choice of sampling media is determined largely by the nature of   used in the study. 
For example, drug levels in a clinical pharmacokinetic study demand the use of blood, urine, and 
saliva. A bioavailability study may require drug level data in blood and / or urine whereas a drug 
identification or drug abuse problem may be solved with only one type of biological sample. 
Department of Pharmaceutical Analysis            Introduction                                                                             
K.M.C.H College of Pharmacy Page 2
Detection of drug or its metabolite in biological media is usually complicated by the 
matrix. Because of this, various types of cleanup procedures involved i.e. solvent extraction and 
chromatography are employed to effectively separate drug components form endogenous 
biological materials. The sensitivity and selectivity of the assay method was limited by the 
efficiency of the clean up methodology.
If the blood is allowed to clot and is then centrifuged, about 30 to 50% of the original 
volume is collected as serum (upper level). Plasma generally is preferred because of its greater 
yield from blood. Blood, serum or plasma samples can be utilized for bioanalytical studies and 
may require protein denaturation steps before further processes.
If plasma or serum is used for the analytical procedure, the fresh whole blood should be 
centrifuged immediately at 5000 rpm for approximately 5 to 10 min, and the supernatant should 
be transferred by means of a suitable device, such as pasture pipette, to a clean container of 
appropriate size of storage.
Urine is the easiest one to obtain from the patient and also permits collection of large and 
frequently more concentrated samples. The lack of protein in a healthy individual’s urine 
obviates the need for denaturation steps, because urine samples are readily obtained and often 
provide the greatest source of metabolites, they are frequently analyzed in drug metabolism 
studies.
PREPARATION AND PRESERVATION OF BIOLOGICAL SAMPLES
Sample preparation is important step for analysis of drugs and metabolites in 
bioanalytical study. Biological samples contain proteins, various endogenous and exogenous 
substances that may interfere with analyte. The objective of sample preparation is to free analyte 
of interest from all possible unwanted substances without significant loss of analyte. When drugs 
are susceptible to plasma esterase, the addition of esterase inhibitors, such as sodium fluoride 
was immediately added after collection helps to prevent decomposition.
When collecting and storing biological samples, there are chances for the analyte to get 
contaminated with storage vessels , For example, plastic containers contains high boiling liquid 
bis (2-ethylhexyl) phthalate; similarly, the plunger-plugs may contain tri-butoxyethyl phosphate, 
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which can be interfere with certain drug analysis. Hence care should be taken in selecting the 
material of containers for sample storage and preservation.
ESTIMATION OF DRUGS BY BIOLOGICAL FLUIDS [6, 7]
The choice of sampling media is determined largely by the nature of the drug study. For 
example, drug levels in a clinical pharmacokinetic study demand the use of blood, urine, and 
possibly saliva. A bioavailability study may require drug level data in blood or urine. Steps 
involved in the estimation of drugs in biological fluid are collection of the sample, sample 
treatment and separation of the compound of interest from the matrix and analysis.
EXTRACTION PROCEDURE FOR BIOLOGICAL SAMPLE [8-10]
Sample preparation is a technique used to clean up a sample before analysis and /or to 
concentrate a sample to improve its detection. When samples are biological fluids such as 
plasma, serum or urine, this technique is described as bioanalytical sample preparation.
Objectives of Bio-analytical sample preparation:-
1. Removal of unwanted matrix components (primarily protein) that would interfere 
with analyte determination.
2. Concentration of analyte to meet the detection limits of the analytical instrument.
3. Exchange of the solvent or solution in which the analyte resides so that it is 
compatible with mobile phase for injection into a chromatographic system.
4. Dilution to reduce solvent strength or avoid solvent incompatibility.
5. Stabilization of analyte to avoid hydrolytic or enzymatic degradation.
After selection of biological fluid the required analyte should be extracted from it. This step 
in bioanalytical method is more important because sample preparation can be done by different 
methods of extraction .The sample preparation is a time taking process and it should be done 
carefully because of its importance. If biological matrix is in liquid state like blood, plasma and 
urine then liquid-liquid extraction is used or it is solid then liquid-solid extraction can be done. 
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Different types of extracting methods are
∑ Dilution followed by injection
∑ Solid Phase extraction (off line/online)
∑ Protein precipitation
∑ Filtration
∑ Liquid-liquid extraction
∑ Protein removal by equilibrium dialysis or ultrafiltration
∑ Restricted access media
∑ Solid-supported liquid-liquid extraction
∑ Monolithic columns
∑ Immunoaffinity extraction
Out of all these methods the most prominent and widely used techniques for extraction are:
ß Protein precipitation method.
ß Liquid-liquid extraction method.(LLE)
ß Solid-phase extraction method.(SPE)
Protein precipitation [11, 12]
Protein precipitation is based on the interaction between the precipitation reagent and 
protein groups. Soluble proteins generally have a hydrophobic core surrounded by a hydrophilic 
surface including ionic groups that are not involved in intra-molecular binding. Organic solvents 
interfere with the intra-molecular hydrophobic interactions of proteins. 
The addition of a volume of solvent (frequently acetonitrile) to the serum causes the 
proteins of the serum to precipitate and leaves the analyte of interest in the solvent, which
can either be injected directly or dried down and reconstituted in a smaller volume to 
concentration before injection. While this is the fastest and simplest method for sample
preparation, it is the most likely to cause ion suppression issues, especially in ESI, where the co-
elution of endogenous compounds such as lipids, phospholipids and fatty acids affect the ESI 
droplet desolvation process. 
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Fig 1: Schematic diagram of protein precipitation technique.
Procedure
a) In case of acids: Take 0.5 to 1.0 ml of plasma/serum/urine and add 100 to 200µl of 10 to 
20 % perchloric acid or trichloroacetic acid or sometimes decreasing the volume and 
increasing the percentage of acid are also recommended.
b) In case of organic solvents: Take 0.5 to 1.0 ml of plasma and add 0.5 to 2.0ml of solvent 
methanol or acetonitrile.
After adding the acid or solvent vortex the vial for complete precipitation of protein 
then centrifuge and inject the supernatant. It is recommended to filter the sample whenever the 
technique is used to avoid clogging of the column.
Liquid-Liquid Extraction [13, 14]
Liquid- liquid extraction is a common technique used to extract analytes from liquid 
matrices Isolation of analyte from interferences is done by partitioning or distribution of the 
sample between two immiscible liquids or phases. Typically, with LLE one phase will be 
aqueous (often the denser or heavier phase) and the second phase is an organic solvent (usually 
the lighter phase). Hydrophilic compounds prefer the polar aqueous phase, whereas hydrophobic 
compounds will prefer the organic solvent. The two phases used in this method should be 
immiscible to each other. It is very useful for separating analytes from interferences by 
partitioning the sample between these two immiscible liquids or phases.
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The basic principle is the tendency of an analyte to prefer one solvent over another 
immiscible solvent. The process is based on the Nernst distribution law, which states that any 
species will distribute between two immiscible solvents so that ratio of the concentrations remain 
constant. The often-quoted partitioning coefficient of a species is Log P which is defined as the 
ratio of the concentration in octanol divided by the concentration in water
Procedure
To the biological fluid two immiscible solvents are added and centrifuged, then the 
organic solvent is evaporated. To ensure rapid equilibrium more surface area is required that is 
achieved by thoroughly mixing or manually shaking. The residue thus obtained is reconstituted 
with the suitable solvent of small volume which is compatible with HPLC separation while 
analytes extracted in aqueous phase can be directly injected into HPLC. More than one sample 
can be extracted in this method. To do this method effectively some steps are present, they are,
∑ To facilitate removal of the extraction solvent at the end with low boiling point is used.
∑ Solvent with low viscosity is used to facilitate mixing with the sample.
∑ Analyte must be soluble in extracting solvent.
∑ The organic solvent selected should have low solubility in water, high purity and should 
be compatible for the HPLC detection techniques.
Fig 2: Schematic representation of LLE process
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Solid Phase Extraction [15-19]
Solid-phase extraction (SPE) is a sample preparation process by which compounds that 
are dissolved or suspended in a liquid mixture are separated from other compounds in the 
mixture according to their physical and chemical properties. Solid phase extraction can be used 
to isolate analytes of interest from a wide variety of biological matrices. SPE uses the affinity of 
solutes dissolved or suspended in a liquid for a solid through which the sample is passed to 
separate a mixture into desired and undesired components. The result is that either the desired 
analytes of interest or undesired impurities in the sample are retained on the stationary phase. 
The portion that passes through the stationary phase is collected or discarded, depending on 
whether it contains the analytes or impurities. If the portion retained on the stationary phase 
includes the desired analytes, they can then be removed from the stationary phase for collection 
in an additional step, in which the stationary phase is rinsed with an appropriate eluent.
Solid–phase extraction method also contains two phases, one is solid and other is liquid phase. 
In this method analyte is retained on the solid phase, while sample passes through, followed by 
elution of an analyte with an suitable solvent. The solid phase used here is plastic disposable 
column or cartridge which is packed with sorbent like reversed phase material (C-18silica) which 
has been bonded a hydrocarbon phases. SPE involves a solid-liquid phase separation of the 
analytes from the biological sample, by the selective transfer between a liquid and solid state. 
The analyte is physically separated from the biological matrix by the differential interacting
with a solid phase sorbent material. These sorbents, packed primarily into either disposable 
cartridges or discs, can be polar, non-polar or ionic depending on the experimental requirements.
The principle of SPE is similar to that of liquid-liquid extraction (LLE), involving a 
partitioning of solutes between two phases. However, instead of two immiscible liquid phases, as 
in LLE, SPE involves partitioning between a liquid (sample matrix or solvent with analytes) and 
a solid (sorbent) phase. This sample treatment technique enables the concentration and 
purification of analytes from solution by sorption on a solid sorbent and purification of extract 
after extraction. The general procedure is to load a solution onto the SPE solid phase, wash away 
undesired components, and then wash off the desired analytes with another solvent into a 
collection tube.
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Mechanism of Solid Phase Extraction Process
Solid phase extraction involves four distinct steps, which is as follows:
a) Conditioning of the packing
b) Loading of the sample
c) Washing the packing/ sorbent
d) Recovery of the analyte
Fig 3: Solid phase extraction separation process
a) Conditioning  of the packing
Prior to the addition of the sample conditioning and packing of the cartridge is done. The 
hydrophobic packing is dry initially and the ligands are all collapsed. Organic phase 
extends the ligands and prepares them for interaction with the analyte.
b) Loading of the sample
A solution containing the sample, as well as, any contaminants or interfering 
substances, is introduced onto the stationary phase by dissolving in a weak solvent.
This weak solvent helps in retention of strong analyte. The stationary phase will interact 
with the analyte molecules, retaining them until the final elution step. As the separation 
of the analytes is achieved by the selective transfer between a liquid and solid state, the analyte is 
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physically separated from the biological matrix by the differential interacting with a solid
phase sorbent material.
c) Washing of the packing / sorbent
Washing step aids in the removal of contaminants and interfering compounds. This step 
is conducted again with the solvent composition of the sample matrix. During this step, the 
analyte will be bound by the stationary phase and will not be released by the column.
d) Recovery of the analyte
An elution solvent is introduced to the column. The elution solvent will have distinctly 
different properties than the solvent used for the previous three steps. For example, considering a 
hydrophobic pharmaceutical compound should the sample be loaded in an aqueous plasma 
solution, an organic solvent such as acetonitrile may be used to elude the compound. Strong 
elution solvent is passed through the cartridge and it gives 100% collection of analyte from this 
method. The eluted solution collected may be evaporated in order to control the concentration.
SOLID PHASE EXTRACTION THEORY 
How compounds are retained by the sorbent 
1) Reversed Phase 
(Polar liquid phase, non polar modified solid phase) 
Hydrophobic interactions 
∑ Non polar-non polar interactions 
∑ Van der Waals or dispersion forces 
2) Normal Phase 
(Non polar liquid phase, polar modified solid phase) 
Hydrophilic interactions 
∑ polar-polar interactions 
∑ hydrogen bonding 
∑ pi-pi interactions 
∑ dipole-dipole interactions 
∑ dipole-induced dipole interactions 
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3) Ion Exchange 
Electrostatic attraction of charged group on compound to a charged group on the   
sorbent’s surface 
4) Adsorption (Interaction of compounds with unmodified materials) 
Reversed Phase SPE
Reversed phase separations involve a polar or moderately polar sample matrix (mobile phase) 
and a non polar stationary phase. The analyte of interests will be typically non polar or less polar 
in nature. Several SPE materials, such as the alkyl- or aryl-bonded silicas (LC-18, ENVI-18, 
LC-8, ENVI-8, LC-4, and LC-Ph) are in the reversed phase category.
Here, the hydrophilic silanol groups at the surface of the raw silica packing (60Å pore size, 
40μm particle size) have been chemically modified with hydrophobic alkyl or aryl functional 
groups by reaction with the corresponding silanes.
The Role of pH in solid phase extraction 
Solutions used in SPE procedures have a very broad pH range. Silica-based packings, 
such as those used in HPLC columns, usually have a stable pH range of 2 to 7.5. At pH levels 
above and below this range, the bonded phase can be hydrolyzed and cleave off the silica 
surface, or the silica itself may dissolve. In SPE, the solutions are usually in contact with the 
sorbent for short periods of time and also since the SPE cartridges are disposable, and are meant 
to be used only once, any pH can be used to optimize retention or elution of analytes. If stability 
of the SPE cartridge at an extreme pH is crucial, then polymeric or carbon-based SPE materials 
may be used as these materials are stable over the pH range of 1-14. 
For reversed phase SPE procedures on bonded silicas, if trapping the analyte in the tube is 
desired, the pH of the conditioning solution and sample should be adjusted for optimum analyte 
retention. If the compound of interest is acidic or basic we can use a pH at which the compound 
is not charged. Retention of neutral compounds is usually not affected by pH. Conversely, you 
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can use a pH at which the unwanted compounds in the sample are retained on the SPE packing, 
but the analyte of interest passes through unretained. For adsorption media that are used under 
reversed phase conditions, a pH should be chosen to maximize retention of analyte on the 
sorbent as with reversed phase bonded silica. Elution is usually done with an organic solvent, so 
pH is usually not a factor at this point. 
Table 1 : Commonly used solvents in solid phase extraction
Analytical methods for quantitative determination of drugs in biological fluids
Numerous methods are employed for the quantitative determination of drugs in biological 
fluids. According to biological fluid and drug to be quantitated these methods are selected. They 
are:
a) Methods based on immunoassay procedure
¸ Radioimmunoassay (RIA).
¸ Enzyme-multiplied immunoassay technique.
¸ Enzyme-linked immunosorbent assay (ELISA).
b) Microbiological methods.
c) Capillary electrophoresis.
d) Chromatographic methods.
¸ Gas chromatography (GC).
¸ High performance liquid chromatography (HPLC).
¸ Liquid chromatography-mass spectroscopy (LC-MS).
¸ Gas chromatography –mass spectroscopy (GC-MS).
Department of Pharmaceutical Analysis            Introduction                                                                             
K.M.C.H College of Pharmacy Page 12
The role of chromatography in bioanalytical studies:
Liquid chromatography with UV or fluorescence detector has been used successfully for 
drug discovery development and clinical trials. Compounds with low circulating levels or low 
dosed compounds such as inhaled products, a method has to be developed with necessary 
sensitivity could take a particular  laboratory time with derivatisation schemes being required. 
For shorter run times the selective ion monitoring (SIM), multiple reaction monitoring 
(MRM) are used to reduce need for complete resolution of analyte in chromatographic method. 
In order, to know the concentration of drug and its metabolites in biological fluids can be done 
by chromatography which are useful in preclinical, clinical and drug discovery and development 
process. The hyphenated techniques such as LC-MS, GC-MS are important for bioanalytical 
studies. In chromatography separation of particular compound is possible and quantity of the 
compound can be also known. The separation of compounds in chromatography is based on 
different principles.
ESTIMATION OF DRUGS IN BIOLOGICAL SAMPLES BY HPLC: [19-22]
High performance liquid chromatography is one of important techniques in 
chromatography. HPLC is an advanced form of liquid chromatography used in separating the 
complex mixture of molecules encountered in chemical and biological systems. HPLC is really 
the automation of traditional liquid chromatography under conditions which provides enhanced 
separations during shorter periods of time. It is ideally suited for separation and identification of 
amino acids, proteins, nucleic acids, hydrocarbons, carbohydrates, pharmaceuticals, pesticides, 
antibiotics, steroids etc. Its simplicity high specificity and wide range of sensitivity make it ideal 
for the analysis of many drugs in both dosage forms and biological fluids. HPLC is a versatile 
analytical tool useful in identification and quantitative estimation of low concentration of drugs 
and metabolites in biological matrices. HPLC is having many advantages most of drugs in 
biological matrix can be estimated by this. Some of its advantages than other methods are:
v Rapid speed. 
v Improved resolution (wide variety of stationary phase).
v Precise and reproducible.
v Easy recovery of sample, handling and maintenance.
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v Greater sensitivity.
v Calculations are done by integrator itself.
v Ideal for substances of low volatility.
v Reusable column
HPLC, revealed by the late Prof. Csaba Horváth for his 1970 Pittcon paper, 
originally presented the fact that high pressure was used to generate the flow required for liquid 
chromatography in packed columns. In the starting, pumps only had a pressure capability of 500 
psi. This is called high pressure liquid chromatography [HPLC]. The early 1970s saw a 
tremendous move in technology. These new HPLC instruments could develop up to 6,000 psi 
[400 bars] of pressure, incorporate improved injectors, detectors and columns. High-performance 
liquid chromatography [HPLC] is now one of the most important tools in analytical chemistry. It 
has the ability to separate, identify and quantitate the compounds that are present in any sample 
that can be dissolved in a liquid. Today, compounds in less concentrations as low as parts per 
trillion [ppt] may easily be identified. Hence HPLC can be applied to any sample, such as 
pharmaceuticals, nutraceuticals, cosmetics, environmental matrices, forensic samples, industrial 
chemicals.
PRINCIPLE:
The principle of separation is based on the typical modes of separation of that of a classical 
chromatography i.e., Adsorption, Partition, Ion exchange and Gel permeation. 
a) Adsorption chromatography
Here the separation of the components on the mixture is achieved by 
adsorption which is a surface phenomenon. It involves the accumulation of the liquid or 
gaseous solute on to the surface of the solid particle. The separation is based on the 
affinity characters of the solutes with solid (stationary phase). Compounds having less 
affinity with the stationary phase will be eluted faster while those compounds with high 
affinity with the stationary phase will elute later.
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b) Partition chromatography
In this method the stationary phase will be liquid coated with solid support. Here the 
separation is achieved based on the relative distribution of solute between the two liquid 
phases i.e., based on their partition co efficient value. This type of chromatography may be 
either Normal phase or Reverse phase depending on the nature of mobile phase and 
stationary phase.
c) Ion –exchange chromatography
This method involves the reversible exchange like sign ions between the stationary ion 
exchange resin and liquid mobile phase. Separation is achieved due to the difference in 
strength of electrostatic interactions of the solutes with the stationary phase.
d) Gel permeation chromatography
Here the mechanical sorting of molecules are based on the size of the molecules in 
solution.  Small molecules are able to permeate more pores and are, therefore, retained longer 
than large molecules and hence large molecules are eluted first.
HPLC is historically divided into two different sub classes based on the polarity of the mobile 
and stationary phases.
1. Normal phase high performance liquid chromatography
2. Reverse phase high performance liquid chromatography
ÿ Normal phase high performance liquid chromatography:
Techniques in which the stationary phase is more polar than the 
mobile phase is call normal phase high performance liquid chromatography.
¸ Stationary Phase –Polar nature e.g.: SiO2, Al2O3.
¸ Mobile Phase – Non-polar nature e.g.: Heptane, hexane, cyclohexane, CHCl3, CH3OH
¸ Mechanism:
ß Polar compounds travels slower and eluted slowly due to higher affinity b/w solute and 
stationary phase.
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ß No polar compound travels faster and eluted first due to lower affinity b/w solute and 
stationary phase.
ß This technique is not widely used in pharmaceutical separation.
ÿ Reverse phase high performance liquid chromatography:
Techniques in which the mobile phase is more polar than the stationary phase is called 
reverse phase high performance liquid chromatography.
¸ Stationary phase – Non-polar nature. e.g.: n-octadecyl, n-octyl, ethyl, phenyl diol
¸ Mobile Phase – polar nature. e.g.: Methanol or Acetonitrile/water or buffers
¸ Mechanism:
ß A polar compound travels faster and eluted first due to lesser affinity b/w solute and 
stationary phase.
ß Non polar compounds travel slower and eluted slowly due to higher affinity b/w solute and 
stationary phase.
HPLC INSTRUMENTATION 
Fig 4: Schematic diagram of HPLC 
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The essential parts of HPLC are:
8 Solvent reservoir
8 Pumps 
8 Injector
8 Column
8 Detector 
8 Recorder 
WORKING PROCEDURE
∑ A liquid mobile phase is pumped under pressure through a stainless steel column containing 
particles of stationary phase with a diameter of 3-10µm.
∑ Degassing and filtration  is needed to remove dissolved air and to eliminate suspended 
particles and organic impurities
∑ The pumps passes mobile phase through column at high pressure and at controlled flow rate.
∑ The analyte is loaded onto the head of the column via a loop valve.
∑ Syringe is used to inject the sample through a self sealing inert septum directly into the 
mobile phase .Sample is introduced in the column without causing interruption to mobile 
phase flow.
∑ Guard column is placed anterior to the separating column and it serves as a protective factor 
that prolongs the life and usefulness of the column.
∑ The separation of a mixture occurs according to the relative lengths of time spent by its 
components in the stationary phase.
∑ The resolving power of a column increase with column length and the number of theoretical 
plate per unit length.
∑ Smaller the particles size of the stationary phase, the better the resolution.
∑ Solute molecule having more affinity towards the stationary phase elutes later and lesser 
affinity gets eluted faster.
∑ Monitoring of the columns effluent can be carried out with a variety of detectors
.
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Quantitative analysis by HPLC: [23- 25]
For quantitative of analysis in HPLC generally three methods are used. They are 
1) External standard method. 
2) Internal standard method.
3) Standard addition method.
External standard method:
In this method standard and sample peak area or height are directly compared. In external 
standard method can be done by using single standard or up to three different standard solutions. 
In this method standard and unknown sample are injected and then the concentration of unknown 
sample can be determined by plotting calibration curve graphically or by numerically using 
response factors. For good quantitation in this method constant chromatographic conditions 
should be maintained for both standard and sample separation.
Internal standard method:
In this method a known quantity of a compound is added to known amount of sample to 
give separate peaks, which compensates the loss of compound of interest during sample 
pretreatment. In order to overcome various analytical errors addition of internal standard is 
commonly is used quantitation method. The compound selected for internal standard should be 
completely separate from the sample and should not interfere it. In chromatographic analysis 
internal standard is added to the compound to be analyzed are desirable, if any loss of compound 
may occur during handling. 
In this way both internal standard and concentration of sample ratio remains constant 
regardless of amount of solution lost.  Any loss of compound of interest will be accompanied by 
the loss of an equivalent fraction of internal standard. The internal standard selected should have 
similar properties of that of the interested compound or any other compound with other 
properties also can be taken. In chromatographic analysis internal standards are frequently used.
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The internal standard used should be added to sample before sample preparation and mixed 
properly. By using response factor (Rf) concentration of sample can be known.
Necessary of internal standard
¸ It should elute closely to the interested compound.
¸ No interferences should present in a completely resolved peak.
¸ Stable one, unreactive with compound of interest, mobile phase and column packing.
¸ Behaved equally to the compound of interest for analysis like pretreatment, derivative 
formation.etc
¸ Not be present in the original ample.
¸ Available in high purity.
¸ It should be added at a concentration, which gives peak area or peak height equal or 
unity with the compound of interest.
Standard addition method:
In this method for the sample solution known amount of standard is added. By plotting 
calibration curve graphically the quantitative analysis is carried out. This method is used for 
sample which contains which contains very small quantity of element to be analyzed. In trace 
analysis also this method is used. By adding the standard to sample solution the peak area is 
increased and concentration of sample will be computed by interpretation.
BIOANALYTICAL METHOD VALIDATION (BMV): [26-28]
A bioanalytical method is a set of procedures involved in the collection, processing, 
storage, and analysis of a biological matrix for a chemical compound. Bioanalytical method 
validation (BMV) is the process used to establish that a quantitative analytical method is suitable 
for biomedical applications. Method validation includes all of the procedures that demonstrate 
that a particular method used for quantitative measurement of analytes in a given biological 
matrix, such as blood, plasma, serum, or urine, is reliable and reproducible for the intended use. 
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Validation involves documenting, through the use of specific laboratory investigations, that the 
performance characteristics of the method are suitable and reliable for the intended analytical 
applications.
Bioanalytical method validation is vital not only in terms of regulatory submission but 
also for ensuring generation of high quality data during drug discovery and development. BMV 
assures that the quantification of analyte in biological fluids is reproducible, reliable and suitable 
for the application. Method validation is a process that demonstrates that the method will 
successfully meet or exceed the minimum standards recommended in the Food and Drug 
Administration (FDA) Guidance for accuracy, precision, selectivity, sensitivity, reproducibility, 
and stability of the developed method.
Need for Bioanalytical Method Validation:
The reason for validating a bioanalytical procedure is to demonstrate the performance and 
reliability of a method and hence the confidence that can be placed on the results. It is mandatory 
that all bioanalytical methods must be validated if the results are used to support registration of a 
new drug or the reformulation of an existing one.  Validation involves documenting, through the 
use of specific laboratory investigations, that the performance characteristics of the method are 
suitable and reliable for the intended analytical applications.
1. It is essential to used well-characterized and fully validated bioanalytical methods to 
yield reliable results that can be satisfactorily interpreted.
2. It is recognized that bioanalytical methods and techniques are constantly undergoing 
changes and improvements; they are at the cutting edge of the technology.
3. It is also important to emphasize that each bioanalytical technique has its own 
characteristics, which will vary from analyte to analyte, specific validation criteria may 
need to be developed for each analyte.
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4. Moreover, the appropriateness of the technique may also be influenced by the ultimate 
objective of the study. When sample analysis for a given study is conducted at more than 
one site, it is necessary to validate the bioanalytical method(s) at each site and provide 
appropriate validation information for different sites to establish inter-laboratory 
reliability.
Types of Bioanalytical Method Validation:
A. Full validation:
The full validation is an establishment of all validation parameters to apply to sample 
analysis for the bioanalytical method for each analyte. It is important 
a) When developing and implementing a bioanalytical method for the first time
b) For a new drug entity
c) When metabolites are added to an existing assay for quantification then Full 
validation is done.
B. Partial validation:
These are modifications to bioanalytical methods for which Full validation is not necessary. 
Modifications done for bioanalytical methods such as, small changes like change in species with 
matrix(from rat plasma to mouse plasma),change in matrix with in a species(from human urine 
to human plasma)change in laboratories or analysts, instruments, change in sampling process 
procedures, change in analytical method like changing detector. 
C. Cross validation: 
In this two bioanalytical methods are compared. The “reference” method which is original 
one is compared with the revised one “comparator”. This is done where two bioanalytical 
methods are compared and from that same data is prepared for study. This is done in two ways. 
Spiked matrix samples and subjected samples validation done at sane site or done at different 
sites i.e. different laboratories or by using different techniques in same laboratory.
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FDA guidelines on bioanalytical method validation: [29, 30]
For bioanalytical method validation FDA had given some guidelines. These guidelines are 
given the validation performed was to be accurate. They are:
ÿ Analyte stability in biological matrix at intended storage and operating conditions should 
be kept.
ÿ Standard curve for matrix-based one should contain minimum 5 standards without 
including blank and it should cover the entire range of concentrations expected.
ÿ Essential parameters that are performed for acceptability of bioanalytical method are 
precision, accuracy, selectivity, sensitivity and reproducibility.
ÿ Then the lower limit of quantitation should serve as lowest concentration on the standard 
curve and that is not confused with limit of detection.
ÿ All these parameters are to be defined during the Full validation of a bioanalytical 
method.
Validation parameters: [31-34]
The common parameters used in the bioanalytical validation is given as follows,
1. Accuracy
2. Precision
a. Repeatability  
b. Intermediate Precision 
c. Reproducibility
3. Linearity / Range
4. Specificity / Selectivity
5. Limit of Detection (LOD)
6. Limit of Quantification (LOQ)
7. Range 
8. Robustness
9. Ruggedness.
10. System suitability
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1) Accuracy:
It is the closeness of mean tests results obtained by the method to true concentration of 
analyte. It is also named as trueness. Accuracy is determined by replicate analysis of samples 
containing known amounts of the analyte. Most commonly used method for determination of 
accuracy is recovery studies. The usual range is being 10% above or below the expected range of 
claim. The % recovery was calculated using the formula,
100
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Where,
a – Amount of drug present in sample
b – Amount of standard added to the sample
Acceptance Criteria:
ÿ In assay method, mean recovery will be 100% ± 2% at each concentration between the ranges of 
80-120% of the target concentration.
ÿ In impurity method, mean recovery will be 0.1% absolute of the theoretical concentration or 10% 
relative, whichever is greater for impurities between the ranges of 0.1-2.5 % (V/W).
2) Precision:
When the procedure is applied repeatedly to multiple samplings of single homogenous 
sample under prescribed conditions then precision, is a closeness of individual measurements of 
the analyte. It is done at three levels such as repeatability, intermediate precision, and 
reproducibility.
Repeatability: It expresses precision under same operating conditions i.e. with in the 
laboratory same analyst using same equipment over a short period of time.
Intermediate precision: It is the precision under different laboratory conditions i.e. varying 
only in different analyst, on different days, or using different equipments within the same 
laboratory.
Reproducibility: It is the precision between different laboratories and is often determined in 
method transfer experiments 
Acceptance Criteria:
¸ Percentage Relative  deviation (%RSD)  NMT 1 % (Instrument precision)
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¸ (%RSD)  NMT -2% (Intra- assay precision)
3) Linearity:
As per ICH definition “the ability to obtain test results which are directly proportional to the 
concentration of an analyte within given range is known as linearity of an analytical procedure”. 
By using correlation coefficient this can be tested. Using correlation coefficient is a benefit as it 
is a relationship between concentration and response data. In this data is analyzed by linear least 
square regression co-efficient and b of the linear equation,                                
Y= aX + b
By the above equation regression r value can be known. For the method to be linear the r value 
should be close to1. Where Y is the measured output signal, X is the concentration of sample, a 
is the slope, b is the intercept.
Acceptance criteria:
Coefficient of correlation should be NLT 0.99.
4) Specificity / selectivity:
A method is said to be specific when it produces proper response only for a single analyte. It can 
be demonstrated by performing Placebo / blank interference and forced degradation studies. If 
the expected impurities or related substances are available, then they should be analyzed along 
with the analyte or sample to check the system suitability, retention factor, tailing factor and 
resolution etc. In this peak purity studies are done for specificity. 
5) Limit of detection (LOD):
The limit of detection is the lowest concentration of analyte in the sample which can be detected 
but not quantified under given experimental conditions. The lowest concentration which can be 
distinguished from the background noise with a certain degree of confidence is defined as limit 
of detection. Prepare the blank solution as per test method and inject six times into the 
chromatographic system. Similarly prepare the linearity solution staring from lowest possible 
concentration of analyte to 150 % (or as per protocol) of target concentration and establish the 
linearity curve.
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The detection limit (DL) may be expressed as:
LOD = 3.3 X Standard deviation of the response of the blank (σ) 
Slope 
The slope shall be estimated from the calibration curve of the analyte.
6) Lower Limit of quantification (LLOQ):
It is also the lowest concentration of analyte in the sample but quantitatively determined with 
suitable accuracy and precision.
In calibration curve it is the lowest concentration point. It is determined by accuracy by the 
presence of background signal and by precision i.e. reproducibility of analyte in the method.
LOD = 10 X Standard deviation of the response of the blank (σ) 
Slope 
Acceptance Criteria:
ÿ In Pharmaceutical application, the LOQ is typically set at minimum 0.05% for active 
pharmaceutical ingredients.
ÿ LOQ defined as the lowest concentration providing a RSD of 5%.
ÿ LOQ should be at least 10% of the minimum effective concentration for clinical applications.
7) Range:
The range of an analytical procedure is the interval between the upper and lower concentration 
(amounts) of analyte in the sample (including these concentrations) for which it has been 
demonstrated that the analytical procedure has a suitable level of precision, accuracy and 
linearity. The range of a bioanalytical assay is the concentration interval over which an analyte 
can be measured with acceptable precision and accuracy.
8) Robustness: 
It is the measure of its capacity to remain unaffected by small, but deliberate variations in 
method parameters and provides an indication of its reliability during normal usage.
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9) Ruggedness:
Ruggedness according to the USP is “the degree of reproducibility of test results obtained by the 
analysis of the same samples under a variety of normal test conditions, such as different labs, 
different analysts, and different lots of reagents. The following are the typical method parameters 
need to test during method validation: 
ÿ Analyst-to-analyst variability.
ÿ Column-to-column variability.
ÿ On different days.
ÿ In different laboratories
Table 2: Method Validation Requirements for Example (ICH)
METHOD   VALIDATION 
REQUIREMENTS
ACCEPTANCE 
CRITERIA
Precision
Assay repeatability
Intermediate precision (Ruggedness)
≤ 1% RSD
≤ 2% RSD
Accuracy
Mean recovery per concentration 100.0% ± 2.0%
Limit of detection
Signal to-to-noise ratio ≥ 3:1
Limit of quantification  
Signal to-to-noise ratio ≥ 10:1
Linearity/Range
Correlation coefficient
y-Intercept
Visual
>0.99
± 10%
Linear
Robustness
System suitability met
Solution stability
yes
± 2% change from time zero
Specificity
Resolution from main peak >2 min. (retention time)
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System suitability:
System suitability testing is an integral part of analytical procedures. System suitability 
test parameters to be established for a particular procedure depend on the type of procedure 
being validated. The simplest form of system suitability test involves a comparison of the 
chromatogram trace with a standard trace. This allows a comparison of the peak shape, peak 
width, and baseline resolution.
These are the parameters that can be calculated experimentally to provide a quantitative system 
suitability test report:
∑ Number of theoretical plates (efficiency)
∑ HETP
∑ Capacity factor,
∑ Peak asymmetry factor
∑ Resolution,
∑ Tailing factor
System Suitability Parameters and Recommendations (ICH Guidelines)
Table 3: System suitability parameters and recommendations
Parameter Formula Recommendation
Theoretical Plates (N) N=5.54*(tR/W0.5)
2 In general should be > 2000
HETP(H) H= L/N HETP↓ Column efficiency↑
Peak asymmetry (As) As= b/a In general it should be 1
Tailing Factor (T) T= (b+a)/2a In general it should be 1
Resolution  (R)
( )
21
122
WW
tt
Rs +
-
Rs of > 2 between the peaks of interest.
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APPLICATION OF A VALIDATED BIOANALYTICAL METHOD TO ROUTINE [35]
In general, biological samples can be analyzed with a single 
determination without duplicate or replicate analysis of the assay method has acceptable 
variability as defined by the validation data, This is ture for procedures where precision and 
accuracy variability’s routinely fall within acceptable tolerance limits.
The following recommendations should be noted in applying a bioanalytical method to routine 
drug analysis:
¸ A matrix-based standard curve should consist of a minimum of five to eight standard points, 
excluding blanks (either single or replicate), covering the entire range.
¸ Response Function: Typically, the same curve fitting, weighting and goodness of fit 
determined during pre-study validation should be utilized for the standard curve within 
study. Response function is determined by appropriate statistical tests based on the actual 
standard points during each run in the validation. 
¸ The QC samples should be used to accept or reject the run. These QC samples are matrix 
spiked with analyte.
¸ System suitability: Based on the analyte and technique, a specific standard operating 
procedure (or sample) can be identified to assure the optimum operation of the system 
employed.
¸ Any required sample dilutions must utilize like matrix (e.g. human to human) obviating the 
need to incorporate actual within-study dilution matrix QC samples.
¸ Repeat Analysis: It is important to establish an SOP or guideline for repeat analysis and 
acceptance criteria. This SOP or guideline should explain the reasons for repeating sample 
analysis.
Bioanalysis and the production of Pharmacokinetic, toxic kinetic and 
metabolic data plays a fundamental role in the pharmaceutical research and development 
involved in the drug discovery and development process. Therefore the data must be 
produced to the acceptable scientific standards and specifications lay by the different 
regulatory agencies worldwide. Bioanalytical methods must be validated to objectively 
demonstrate the fitness for their intended use.
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2. LITERATURE REVIEW [36-47]
SLNO: AUTHOR NAME OF THE 
JOURNAL
TITLE OF THE 
ARTICLE
ANALYTICAL 
CONDITIONS
1
Rajendra B. 
Kakde et al.,
Journal     of 
Chromatographic 
Science
(2013)
Stability-Indicating
RP -HPLC Method 
for the Simultaneous 
Determination of 
Escitalopram
Oxalate and 
Clonazepam
SP: ODS Hypersil C18 
column (250,x 4.6 mm)
MP: Mixture of 
acetonitrile 50 mM & 
phosphate buffer 10
mM,triethylamine 
(70:30 v/v)
FR:  1.0 ml/min
λ: 268 nm
2 Bhimanadhuni 
et al.,
International 
Current 
Pharmaceutical 
Journal
(2012)
Development and 
validation of an RP-
HPLC method for 
the simultaneous 
determination of 
Escitalopram 
Oxalate and 
Clonazepam in bulk 
and its 
pharmaceutical 
formulations
SP : Hypersil ODS C18 
column (250 mm X 4.6
mm; 5μ)
MP: Mixture of buffer and 
acetonitrile ( 50:50 v/v)
FR: 1.0 ml/min
λ  :  240 nm
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3 R. D. Chakole
et al.,
International 
Journal of 
Phytopharmacy
(2012)
Simultaneous 
estimation of 
escitalopram and  
clonazepam by RP-
HPLC in  various  
pharmaceutical 
formulations
SP : C18 column ( 250 × 
4.6 mm, 5 μ)
MP: Mixture of methanol 
and buffer of pH 4.0
(90:10 v/v)
FR: 1.0 ml/min
λ  : 248 nm
4 Bhosale 
Suryakant D
et al.,
Journal of 
pharmaceutical 
and biomedical 
sciences
(2012)
RP-HPLC Method 
for simultaneous 
estimation of 
Escitalopram 
Oxalate and 
Etizolam in a tablet 
formulation
SP: HiQ-sil C18 HS
column (250 x 4.6 mm) 
MP: Mixture  of methanol 
and phosphate buffer pH-5 
(70:30,v/v)
FR: 1.0 ml/min
λ : 254 nm
5 Lasan V M
et al.,
International 
Journal for 
Pharmaceutical 
Research Scholars
(2012)
Analytical Method 
Development and 
Method Validation 
for Escitalopram 
Oxalate in 
Pharmaceutical 
Dosage Forms by 
HPLC Method
SP : Inertsil ODS-2 C18 
column (250 x 4.6 mm, 5
μm)
MP: Mixture of potassium 
dihydrogen phosphate 
buffer (pH  3.8 adjusted 
with OPA) and acetonitrile 
and methanol 
(670:280:50v/v/v)
FR: 1.0 ml/ min
λ  : 238 nm
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6 Tapobana 
samanta et al.,
International 
journal of 
chemistry research
(2011)
RP-HPLC method 
for the estimation of 
escitalopram in bulk 
and in dosage
forms
SP : Xterra RP C18
column (150 mm ×4.6 mm, 
5 μm)
MP :  Mixture of
phosphate buffer pH 7.0
and an organic mixture 
acetonitrile and methanol 
(55: 45 v/v)
FR : 1.2ml/min
λ :  238nm
7 Carlos E.M. 
de SOUSA
et al.,
Latin American 
Journal of 
Pharmacy
(2012)
Determination of 
Escitalopram in 
Human Plasma by 
High
Performance Liquid 
Chromatography-
Tandem Mass 
Spectrometry (LC-
MS)
SP: ACE C18 Column
(125 x 4,6 mm) 
MP: Mixture of 
acetonitrile and 0.2 % 
formic acid in water  
(60:50 v/v)
Detection Method: Triple 
quadrupole mass 
spectrometer equipped 
with an electrospray 
ionization source for mass 
detection
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8
Pallavi alegete
et al.,
International 
journal of 
pharmacy
(2016)
Simultaneous 
quantification of  
Risperidone     and 
Escitalopram oxalate 
in  human plasma by  
LCMS/MS: 
application to a 
pharmacokinetic
Study
SP: x-terra RP8 column 
(50 mm × 4.6, 5μm)
MP: Mixture of 
acetonitrile:ammonium 
acetate buffer 5 mm, pH
5.0±0.05
Detection method: 
Tandem mass 
spectrometric assay
9
Mahadeo V. 
Mahadik
Eurasian Journal 
of Analytical 
Chemistry
(2007)
Application of 
Stability Indicating 
HPTLC Method for
the
Quantitative 
Determination of 
Escitalopram 
Oxalate in
Pharmaceutical 
Dosage Form
SP: TLC  aluminium  
plates precoated  with  
silica  gel  60F-254
MP:Mixture of Toluene: 
Acetone: Ethanol: 
Ammonia (5:1:1:0.2 v/v)
Detection method:
analysis at 239 nm
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10 Bhumika D. 
Sakhreliya et 
al.,
Journal of 
Pharmaceutical 
Science and 
Bioscientific 
Research (JPSBR)
(2012)
Development and 
Validation of U V    
Spectrophotometric 
Methods for 
Simultaneous 
Estimation of 
Escitalopram oxalate 
and Etizolam in their 
Combined Tablet 
Dosage Form
Solvent :  0.1 N HCl
Method I :
simultaneous equation 
method λmax of  
Escitalopram oxalate 238.2 
nm and λmax of Etizolam 
251.6 nm
Method II :
Q ratio (absorbance ratio) 
method 238.2 nm and 
248.8 nm (isoabsorptive 
point)
Method III:
absorbance correction 
method absorbance 
measurement at 238.2 nm 
for Escitalopram oxalate 
and 292.8 nm for Etizolam
11 Santhosh 
D.shelke
et al.,
Journal of 
Chemical and 
Pharmaceutical 
sciences
(2009)
Development and 
validation of U V
Spectrophotmetric 
method of escitalopram 
oxalate in bulk and 
pharmaceutical 
formulations
Solvent: 0.1 N HCl
λmax :239 nm
12 Sharma S
et al.,
Journal of Young 
Pharmacists
(2010)
Zero order – UV
spectrophotomteric 
method for estimation 
of escitalopram oxalate 
in tablet formulations
Solvent : 80% v/v aqueous 
methanol
λmax : 238 nm
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3. DRUG PROFILE [48-53]
ESCITALOPRAM OXALATE
1. Chemical profile:
Synonyms:
Escitalopram, (s) - citalopram, (+) - citalopram
Brand name:
Lexapro, Estilo, Citalex, Nexito, Etilopram
Chemical name/ IUPAC Name:
S-(+)-1-[3-(dimethyl-amino) propyl]-1-(p-fluorophenyl)-5-phthalancarbonitrile oxalate.
Molecular formula:
C20H21FN2O•C2H2O4
Molecular mass: 414.40 g/mol
Structure:
Fig 5: Molecular structure of escitalopram oxalate
.C2H2O4
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Pharmacokinetic data:
Bioavailability    : 80% relative to an intravenous dose
Metabolism  : Hepatic (N-de methylation reaction using CYP3A4 and CYP2C19 
enzymes)
Protein binding :   ~56%
Half life : 27-32 hours
Excretion : Renal (10%)
Routes : Oral
Description:
Escitalopram oxalate occurs as a fine, white to slightly-yellow powder and is 
freely soluble in methanol and dimethyl sulfoxide (DMSO), soluble in isotonic saline 
solution, sparingly soluble in water and ethanol, slightly soluble in ethyl acetate, and 
insoluble in heptane .
Category:
Selective serotonin reuptake inhibitor (SSRI) which is under the category of 
antidepressant drugs.
Dose:
For the treatment of depression it is basically 10-20 mg/ day and for elderly 
persons it will be 5-10 mg/day. Escitalopram tablets (LEXAPRO) are film-coated, round 
tablets contains escitalopram oxalate in strengths equivalent to 5 mg, 10 mg, and 20 mg 
escitalopram base.
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Indications:
Labeled indications include major depressive disorder (MDD) and generalized 
anxiety disorder (GAD). Unlabeled indications include treatment of mild dementia-
associated agitation in nonpsychotic patients
2. Pharmacological profile:
Mechanism of action:
The antidepressant, antiobsessive-compulsive, and antibulimic actions of 
escitalopram are presumed to be linked to its inhibition of CNS neuronal uptake of 
serotonin. Escitalopram blocks the reuptake of serotonin at the serotonin reuptake pump 
of the neuronal membrane, enhancing the actions of serotonin on 5HT1A auto receptors.
Antidepressant action of escitalopram is linked to potentiation of serotonergic activity in 
the central nervous system (CNS) resulting from its inhibition of CNS neuronal reuptake 
of serotonin (5-HT). Escitalopram also does not bind to, or has low affinity for, various 
ion channels including Na+, K+, Cl-, and Ca++ channels .Similar to other SSRIs,
Escitalopram also bind with significantly less affinity to histamine, acetylcholine, and 
norepinephrine receptors than tricyclic antidepressant drugs.
Pharmacodynamics:
Escitalopram is one of a class of antidepressants known as selective serotonin 
reuptake inhibitors (SSRIs). It is used to treat the depression associated with mood 
disorders. It is also used on occassion in the treatment of body dysmorphic disorder and 
anxiety. The antidepressant, antiobsessive-compulsive, and antibulimic actions of 
escitalopram are presumed to be linked to its inhibition of CNS neuronal uptake of 
serotonin. In vitro studies show that escitalopram is a potent and selective inhibitor of 
neuronal serotonin reuptake and has only very weak effects on norepinephrine and 
dopamine neuronal reuptake. Escitalopram has no significant affinity for adrenergic 
(alpha1, alpha2, beta), cholinergic, GABA, dopaminergic, histaminergic, serotonergic 
(5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors; antagonism of such receptors has 
been hypothesized to be associated with various anticholinergic, sedative, and 
Department of Pharmaceutical Analysis Drug Profile                                                                            
K.M.C.H College Of Pharmacy Page 39
cardiovascular effects for other psychotropic drugs. The chronic administration of 
escitalopram was found to downregulate brain norepinephrine receptors, as has been 
observed with other drugs effective in the treatment of major depressive disorder. 
Escitalopram does not inhibit monoamine oxidase. 
Drug interactions:
Some medicines may interact with escitalopram like, Buspirone, Fenfluramine 
derivatives, anticoagulants, some diuretics, Tramadol, Carbamazepine or 
Cyproheptadine etc as some has risk of seizures may be increased or some may decrease 
Escitalopram's effectiveness.
Adverse reactions:
Signs of overdose include convulsions, coma, dizziness, hypotension, insomnia, 
nausea, vomiting, sinus tachycardia, somnolence and ECG changes (including QT 
prolongation).
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4. AIM AND OBJECTIVE
Escitalopram is one of the novel antidepressant drugs belonging to the group 
of selective serotonin reuptake inhibitors (SSRI) for the treatment of various 
affective disorders.
The drug dosage is individualized by maintaining the plasma or blood drug 
concentration within the targeted therapeutic window. It is important to understand 
the relationship between plasma and tissue concentrations of drugs and the factors 
that can cause variations in drug concentration. Therapeutic Drug Monitoring 
provides an indirect measurement of drug concentration at effector sites in tissue 
compartments of interest. Hence, there is a need to develop simple, rapid, reliable 
and cost effective analytical method for the clinical routine drug monitoring and 
pharmacokinetic study.
HPLC being a versatile analytical tool for the identification and quantitative 
estimation of low concentration of drugs and metabolites in biological matrices, the 
present study aims to develop 
∑ A precise, accurate, rapid and sensitive analytical method for the estimation 
of Escitalopram oxalate in human plasma.
∑ A simple and precise, solid phase extraction for sample preparation.
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5. PLAN OF WORK
HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC 
METHOD:
Bioanalytical method development for Escitalopram oxalate:
The present work is planned to two phases.
v PHASE  I
1. Optimization of chromatographic conditions
ÿ Selection of wavelength
ÿ Selection of initial separation conditions
ÿ Selection of mobile phase ( pH, peak modifier, solvent strength, 
ratio and flow rate)
ÿ Selection  of the stationary phase
ÿ Selection of  internal standard 
ÿ Sample preparation by solid phase extraction method                        
ÿ Estimation of escitalopram oxalate in human plasma
v PHASE II
2. Validation of the developed method
The developed method were proposed to be validated using various 
validation parameters such as,
ÿ Accuracy
ÿ Precision
ÿ Linearity
ÿ Limit of Detection (LOD) 
ÿ Lower  Limit of Quantitation (LLOQ)
ÿ Selectivity / Specificity
ÿ System suitability.
ÿ Ruggedness
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6. METHODOLOGY
 MATERIALS AND INSTRUMENTS USED:
a) Drug sample and study products:  
Escitalopram oxalate and Tinidazole were procured from Aurobindo Pharma, 
Hyderabad, India              
Plasma: Blank plasma was collected from Hi-tech laboratory, SITRA, 
Coimbatore
b) Chemicals and solvents used :
 Acetonitrile (HPLC grade)
 Methanol (HPLC grade)
 Ortho phosphoric acid (Analytical grade)
 HPLC grade water was prepared by using Millipore MilliQ water 
purification system.
c) Instruments used:
 Elico pH meter LI 127.
 Shimadzu LC-20 AT HPLC.
 SPD-M20A Prominence diode array detector.
 Shimadzu 1600 LC-UV Spectrophotometer.
 Sonica ultrasonic cleaner. 
 Solvent filtration unit – Millipore.
 Shimadzu electronic balance AY 220.
 Ultra cooling centrifuge – Remi, India
 SPE catridge – strata TM-X (Phenomenex)
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 METHOD DEVELOPMENT AND OPTIMIZATION OF 
CHROMATOGRAPHIC CONDITIONS FOR THE ESTIMATION OF 
ESCITALOPRAM OXALATE
i. Selection of Wavelength:
An UV spectrum of 10 µg/ml escitalopram oxalate in methanol was recorded by 
scanning in the range of 200nm to 400 nm. From the UV spectrum, wavelength of 
240nm was selected as the drug showed good absorbance at this wavelength.
ii. Selection of chromatographic method :
Selection of proper chromatographic method depends on the nature of sample 
properties like ionic/ ioinizable /neutral character, its molecular weight and solubility. 
The drug selected for the study was polar in nature. Hence Reverse phase HPLC or ion-
pair or ion exchange chromatography must be used. The RP-HPLC method was selected 
for the initial separations because of its simplicity and suitability.
iii. Initial chromatographic conditions for separation of Escitalopram oxalate:
Thousand µg/ml of escitalopram oxalate was prepared by dissolving 10 mg of 
escitalopram oxalate in 10 ml of HPLC grade methanol. A gradient run was performed 
for the initial separation. From this the appropriate ratio of the organic phase and the 
aqueous required to elute the analyte from the column was determined. An aliquot of the 
mixed standard solution containing 10 μg/ml of drug was prepared and chromatographed 
using the following chromatographic conditions:
 Stationary phase : C8/C18 column
 Mobile phase :   Solvent A – 0.2% Ortho Phosphoric Acid 
                                                       Solvent B – Acetonitrile
 Solvent ratio :   Gradient run, 10 to 100 % solvent B
 Flow rate                    :   0.8 to 1.5 ml/min
 Sample injector         :   Rheodyne 7125 injector
 Sample size               :   20 μl
 Temperature               :  Room temperature (25ºC)
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From the above gradient run, the approximate percentage of acetonitrile in the 
0.2% ortho phosphoric acid solution required to elute the drugs from the column was 
determined. This ratio was used for subsequent isocratic separation and the 
chromatogram was recorded. 
To optimize the chromatographic conditions, the effect of chromatographic 
variables such as mobile phase pH, solvent strength, flow rate, solvent ratio and the 
nature of stationary phase on the peak separation were studied. The resulting 
chromatograms were recorded and the chromatographic parameters such as capacity 
factor, asymmetric factor, and resolution and column efficiency were calculated. The 
conditions that give the best resolution, symmetry and capacity factor were selected for 
the estimation.
a) Effect of pH
The standard solution was chromatographed for 20 minutes using acetonitrile or 
methanol in buffer solutions of different pH ranging from 2.0-7.0 (ortho phosphoric acid 
solutions and phosphate buffer of pH 2.0 and 3.0) as the mobile phase at a flow rate of 
1.5 or 1 ml/min.
b) Effect of nature of stationary phase
Different reversed phase stationary phases (C8 and C18) were used and the 
chromatograms were recorded. When C8 columns were used, the retention time and the 
separation between the peaks were reduced. Hence C18 column is preferred.
c) Effect of solvent strength
Different mobile phases, namely, acetonitrile and methanol were used at a flow 
rate of 1.5 or 1 ml/min. The ratio of acetonitrile or methanol was substituted by the other 
solvents; their solvent to buffer ratios was calculated. The resulting ratios of the mobile 
phase were prepared and the drugs were chromatographed.
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d) Effect of ratio of the mobile phase
The standard solution was chromatographed with mobile phases of different ratios 
of organic and aqueous phases at a flow rate of 1.2 and 1 ml/min.
e) Flow rate
The standard solution was chromatographed at different flow rates namely 1.2, 
1.0 and 0.9 ml/min.
f) Selection of internal standard
Based upon polarity and solubility, tinidazole, ornidazole, and diclofenac sodium
were selected and chromatographed along with the standard drug. The elution time of 
tinidazole was 4.7 min. The peak of tinidazole was symmetric and well resolved from the 
peak of the escitalopram. Hence, for the present study tinidazole was selected as the 
internal standard.
PRETREATMENT METHOD FOR BIOLOGICAL FLUID:
Method of sample preparation is an important criterion for biological samples. For 
the present study plasma was obtained from HI- TECH Clinical Laboratory Services, 
Coimbatore. Solid Phase Extraction (SPE) method was selected for the present study.
Preparation of Standard solutions:
Ten milligrams of standard escitalopram oxalate and internal standard were 
separately dissolved in the few ml of methanol and made up the volume with methanol. 
Serial dilutions were made with mobile phase to get a final concentration of 1 mg/ml.
Preparation of working standards:
From the stock solution 1 ml was taken and diluted to 10 ml(100 µg/ml), from 
this solution 1 ml was further diluted to 10 ml(10µg/ml).From this 1ml was taken and 
diluted to 10 ml(1µg/ml) from the resulting solution 1ml was taken and diluted to 10 ml 
gives100 ng/ml solution.100, 200, 400 ,600, 800 ng/ml solutions were prepared by 
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diluting 1.0 ml, 2.0 ml, 4 ml, 6 ml and 8 ml respectively. In the similar way the working 
standards were prepared for internal standard also.
Plasma spiking procedure:
Hundred micro litre of drug and internal standard were added to 0.5 ml plasma 
and vortexed for 2 mins. To this 1 ml ACN was added and again vortexed for 2-3 mins. It 
was then centrifuged at 3000 rpm for 5 mins and the supernatant was collected and 
refrigerated until analysis.
Extraction by SPE
Solid Phase Extraction (SPE) is the most powerful sample preparation technique 
in common use now a day, where it involves the use of chromatographic sorbent in a 
column format.
Before sample extraction the solid phase extraction cartridge were conditioned 
with 1.0ml of methanol followed by 1.00ml of purified water and 1.00ml of 2% ortho 
phosphoric acid buffer solution. Prepared plasma samples were then loaded on to the SPE 
cartridges and eluted completely under slow vacuum and the cartridges were then washed 
with 1.00 ml 2% ortho phosphoric acid buffer solution and 1.00 ml of methanol and 
allowed to dry. The analyte and the internal standard were then eluted with 1.00ml 
acetonitrile. The eluted samples were then injected into the HPLC system.
The chromatograms of plasma extracted with methanol, acetonitrile and 
methanol–acetonitrile mixture, were recorded using the fixed chromatographic 
conditions. The chromatogram of blank plasma without any drug was also recorded. 
Based up on the percentage recovery acetonitrile was selected as eluting solvent for the 
present study because of its higher percentage recovery.
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Preparation of Standard Graph:
Preparation of calibration standards:
SPE cartridge was conditioned with 1.0 ml of methanol followed by 1.0 ml of 
purified water and 1.0 ml of 2% ortho phosphoric acid buffer solution. Prepared plasma 
samples were then loaded on to the SPE cartridges with the drug concentration of 
100,200,400, 600 and 800 ng/ml respectively. The cartridges were then washed with 1.00
ml 2% ortho phosphoric acid buffer solution and 1.00 ml of methanol and allowed to dry. 
The drug was then eluted with1.0ml acetonitrile. A quantity of 20 µl was injected into the 
HPLC column and chromatograms were recorded. Standard calibration graph was plotted 
using ratio of peak area of escitalopram oxalate to its concentration.
ESTIMATION OF ESCITALOPRAM OXALATE IN HUMAN PLASMA:
Recording the chromatogram:
The optimized chromatographic conditions were maintained to record the 
chromatograms of the calibration standards of escitalopram oxalate and internal standard.
First, baseline stabilization was done for about 20 minutes. Then standard solutions, 
calibration standard solutions and sample from clinical study containing escitalopram 
oxalate were injected and chromatograms were recorded.  
VALIDATION OF THE METHOD 
After developing a method its validation is necessary to prove the suitability of 
the method for the intended purpose. Here the procedure followed for the validation of 
the developed method is described. 
a) Precision:
Intraday and interday precision studies were conducted. In intraday precision 
plasma sample containing drug at three different concentrations with internal standard 
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were injected and chromatogram was recorded. Similarly interday precision over a two 
week period time was evaluated.
Acceptance criteria: 
RSD of the mean concentration of five readings should be less than 15% for 
bioanalytical method.
b) Accuracy:
It is the closeness of mean tests results obtained by the method to true 
concentration of analyte. It is also named as trueness. In this studies the selected 
concentration of the plasma were injected six times and mean peak area for each 
concentration was calculated. Concentration of the each injection was calculated and 
the standard deviation between the readings is calculated. To bioanalytical study the 
percentage RSD should be less than 15%.
c) Recovery studies:
The relative recovery of drug from plasma was calculated by comparing the 
readings of concentration obtained from the drug spiked plasma to that of equal 
concentration from standard sample. Recovery studies were carried out six times for
sample concentration at three levels within the calibration curve.
Acceptance Criteria:
                   For an assay method, mean recovery should be 85-105% ± 2%.
d) Linearity and Range:
Linearity and range were estimated by using calibration curve. By using 
calibration standards prepared by spiking plasma (Escitalopram oxalate) and internal 
standard (Tinidazole) at different concentrations like 100ng/ml to 800ng/ml the 
calibration graph was plotted taking concentration of spiked plasma on x-axis and 
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peak area on y-axis. The linearity is determined from 50% to 150% of the proposed
concentration.
Acceptance Criteria:
                Coefficient of correlation of the calibration should be not less than 0.99
e) Lower Limit of Quantification (LLOQ):
The LLOQ is determined by using the calibration curve. Limit of quantitation 
is the concentration of substance in the sample that will give a signal-to-noise ratio of 
10:1. Detection limit corresponds to the concentration that will give a signal-to-noise 
ratio of 3:1. The signal to noise ratio were performed by comparing measured signal of 
blank plasma sample with those of known low concentration of drug.
f) Specificity:
Specificity of the method was demonstrated by using diode array detector 
peak purity test. The diode array spectrum of both standard and sample peak were 
recorded and compared. The other way for doing specificity based in measurement of 
absorbance ratio of drug peaks at two different levels. The retention time (Rt), 
resolution factor (Rs) and tailing factor (T) were noted for the peaks of escitalopram 
oxalate. Peak purity study is done to prove that a developed method is specific for the 
drug of interest.
Acceptance criteria:
             Purity angle should be less than purity threshold i.e.0.99-1.00
g) Stability:
Stability of the sample, standard and reagent used in HPLC method is required 
for a reasonable time to generate reproducible and reliable results. Stability of plasma 
sample spiked with drug were subjected to three freeze-thaw cycles, short term stability 
at room temperature for 3 hours and long term stability at –200C for four weeks. In 
addition, stability of standard solution and internal standard were performed at room 
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temperature for 6 hours and under frozen condition for two weeks. The stability of this 
solution was studied by performing the experiment and looking for changes in separation, 
retention and asymmetry of the peak which were then compared with the pattern of 
chromatogram of freshly prepared solutions.
h) Selectivity:
Selectivity is the analytical method ability to differentiate and quantify the 
analyte in the presence of other components in the sample. The selectivity was 
established by two different methods.
Method I: Chromatograms of six blank plasma samples were compared with 
chromatogram obtained from standard solutions. Each chromatogram was tested for 
interferences due to endogenous plasma component on the retention times of the selected 
drugs.
Method ІІ: This method involves the peak purity test method using diode array detector. 
The PDA spectrum, UV spectrum, absorbance ratio curve and first derivative spectrum of 
the standard and sample peaks was recorded using PDA detector and compared for the 
peak purity of drug.
i) Robustness:
The robustness of the method was studied by changing the chromatographic 
conditions slightly. The standard solutions were injected in these changed 
chromatographic conditions. 
 ± 1 % difference in the ratio of acetonitrile in the mobile phase.
 ± 0.5 difference in units of pH of the buffer.
 ± 1 % difference in flow rate of the mobile phase. 
In these changed conditions the separation factor, retention time and peak 
symmetry was calculated. Deviation in results from original run should be less than 2%.
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j) System suitability studies:
In system suitability studies certain parameters were calculated namely, column 
efficiency, resolution, capacity factor by repeated injection of standard solutions. As 
specified in the USP these systems suitability studies were carried out.
Capacity factor (k’) it is measurement of sample molecule how good is retained by a 
column during separation. The ideal k value ranges from 2-10.
                                                Capacity Factor (k') = V1 – V0 / V0
               Where, V1 is the retention volume at the apex of the peak (solute)   and V0 is the 
void volume of the system.
Resolution (Rs) is the difference between the retention times of two solutes divided by 
their average peak width. The ideal value of (Rs) is 1.5
Resolution (Rs) = Rt1 –Rt2 /0.5(W1-W2)
Where, Rt1 and Rt2 are the retention times of component 1 and 2, respectively.
Column Efficiency (N) of a column is measured by the number of theoretical plates per 
meter. For ideal good separation, column efficiency N value ranging from 5,000 to 
100,000 plates/meters.
                                      Column efficiency (N) = Rt2 / W2
                 Where Rt is the retention time and W is the peak width.
Peak asymmetry factor- For better column performance it was calculated by the 
formula. When asymmetry factor of value 0.9 to 1.1 then it is achievable for a well 
packed column.
                                           Peak asymmetry factor (As) = b / a
Where a and b are the distances on either side of the peak midpoint.
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Table 4: System suitability parameters and recommendations
Parameter Recommendation
Capacity Factor 
(k’)
The peak should be well-resolved from 
other peaks and the void volume, generally 
k’ > 2.0
Repeatability RSD < / = 1 % for N > / = 5 is desirable.
Relative retention
Not essential as long as the resolution is 
stated.
Resolution (Rs)
Rs of > 2 between the peak of interest and 
the closest eluting   potential   interferent   
(impurity, excipient, degradation product, 
internal standard, etc.)
Tailing Factor (T) T of < / = 2
Theoretical 
Plates(N)
In general should be > 2000
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7. RESULTS AND DISCUSSION
HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC METHOD 
A bioanalytical RP-HPLC method was developed for the escitalopram oxalate. The 
chromatographic conditions were stabilized in order to provide a good performance of the 
assay. The standard and internal standard solutions were prepared and chromatograms were 
recorded. The study proposes a method for the determination of escitalopram oxalate by 
solid phase extraction using RP-HPLC.
Optimization of chromatographic conditions:
i) Selection of wavelength:
The sensitivity of a HPLC method depends upon the proper selection of the 
wavelength. The overlay spectrum of escitalopram oxalate is given in Figure (Fig 6)
Fig 6: Overlay spectrum of Escitalopram oxalate
From the UV spectrum, wavelength of 240 nm was selected. At this wavelength the drug 
showed good absorbance.
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ii) Initial chromatographic conditions:
Acetonitrile was selected as organic phase to elute the drug from the 
stationary phase because of its favorable properties. For the HPLC separation 0.2%
ortho phosphoric acid solution was selected as aqueous phase because of the nature of the
selected analytes. The ratio of organic phase and mobile phase was altered to get better
separation and resolution of the compounds.
Phosphate buffer of pH 2 was tried as aqueous phase for the better result, but there
is no much difference in the peak shape and intensity. So acidic solution of 0.2% ortho
phosphoric acid was fixed as aqueous phase and the ratio was altered step by step to get a
proper resolution and sharp peak.
ÿ Chromatographic condition – 1
Stationary phase                 : Enable C18 column
Mobile phase                      : Solvent A – water
Solvent B - Acetonitrile 
Solvent ratio                       : 50: 50 (A: B)
Detection Wavelength      : 240 nm
Flow rate                            : 1.0 ml/min
Sample size  : 20 µl
For the above chromatographic condition no significant peak was obtained hence an acid
mobile phase was selected for next trial.
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ÿ Chromatographic condition – 2
Stationary phase          : Enable C18 column
Mobile phase                 : Solvent A – 0.2% OPA (O-Phosphoric acid)
Solvent B - Acetonitrile 
Solvent ratio                  : 50: 50 (A: B)
Detection Wavelength   : 240 nm
Flow rate                         : 1.0 ml/min
Sample size  : 20 µl
Fig 7: Chromatogram of escitalopram oxalate
At the above chromatographic conditions escitalopram oxalate was eluted at the 
retention time of 2.5 min. The peak observed posses asymmetric peak characteristics, hence 
not selected for the study
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ÿ Chromatographic condition – 3
Stationary phase            : Enable C18 column
Mobile phase                : Solvent A – 0.2% OPA(O-Phosphoric acid)
Solvent B - Acetonitrile 
Solvent ratio                 : 60: 40 (A: B)
Detection Wavelength   : 240 nm
Flow rate                        : 1.0 ml/min
Sample size  : 20 µl
Fig 8: Chromatogram of escitalopram oxalate
At the above chromatographic conditions escitalopram oxalate was eluted at the 
retention time of 7.8 min. For the further improvement of chromatographic pattern i.e, to 
increase the retention time of escitalopram oxalate and to optimize the internal standard, 
the acetonitrile concentration was further decreased.
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ÿ Chromatographic condition – 4
Stationary phase           : Enable C18 column
Mobile phase              : Solvent A – 0.2% OPA (O-Phosphoric acid)
Solvent B - Acetonitrile 
Solvent ratio                 : 65: 35 (A: B)
Detection Wavelength   : 240 nm
Flow rate                        : 1.0 ml/min
Fig 9: Chromatogram of escitalopram oxalate
Escitalopram was eluted at 10.5minutes. Peaks were also well resolved and symmetric with 
perfect peak properties, hence selected for further studies
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iii) Selection of internal standard
Based upon polarity and solubility, tinidazole, ornidazole, and diclofenac were
selected and chromatographed along with the standard drug. The elution time of tinidazole 
was 4.9 min. The peak of tinidazole was symmetric and well resolved from the peak of the 
escitalopram. Hence, for the present study tinidazole was selected as the internal standard.
Fig 10: Chromatogram of both internal standard and escitalopram
FIXED CHROMATOGRAPHIC CONDITION
Stationary phase                :        Enable C18 column
Mobile phase                     :        Solvent A – 0.2% Ortho PhosphoricAcid in water
Solvent B – Acetonitrile
Solvent ratio                      :        65:35 (A: B) 
Detection Wavelength        :        225 nm
Flow rate                            :        1.2 ml/min
Sample size                        :        20 µl
Needle wash                     :        HPLC grade water followed by methanol
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Temperature                    :        Room temperature (25ºC)
Fig 11: Typical chromatogram obtained for the tinidazole and escitalopram oxalate
The retention time of escitalopram oxalate and internal standard (tinidazole) was 
4.9 and 10.5 min respectively with percent RSD of less than 2%. The results are shown in 
table (Table 5). The peak purity study reveals that signal ratios (relative absorbance at 
different wavelengths) were constant across the peak proﬁle of escitalopram oxalate. The 
peaks obtained in the present study were symmetric, good and no interference was 
observed between the peaks. The method developed was advantageous than the reported 
methods by its lesser precision values and increased accuracy values.
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Table 5: Retention time of escitalopram oxalate and tinidazole (IS)
Chromatographic separation of Escitalopram oxalate in biological fluid:
The chromatogram of the blank plasma was recorded at the fixed chromatographic 
conditions and shown in figure (Fig 12)
Fig 12:  Chromatogram of blank plasma
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Various eluting solvents were used for extraction of Escitalopram oxalate in human 
plasma. The eluting solvents used were methanol, acetonitrile and mixture of methanol and 
acetonitrile, maximum recovery percentage was found in acetonitrile. The percentage 
recovery was calculated and shown in Table 6.
The extraction method used for the present study was simple and newer than 
previous methods. For present study ACN is used as the eluting solvent because of its 
maximum recovery of drug from plasma and it is advantageous.
Table 6: Recovery study of escitalopram oxalate
Level
Conc. 
of
drug 
added
(ng/ml)
Amt. of drug recovered from 
plasma (ng/ml)
% Recovery
Methanol
ACN and 
methanol 
mixture
ACN
Methano
l
ACN and 
methanol  
mixture
ACN
I 50 32.4 34.4 48.2 64.8 68.8 96.4
II 100 74.6 78.2 97.2 74.6 78.2 97.2
III 150 121.4 118.5 147.4 80.9 78.9 98.2
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Fig 13: Chromatogram of escitalopram oxalate and internal standard without SPE
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METHOD VALIDATION 
a) Accuracy and precision: 
At two –levels these accuracy and precision studies were conducted i.e. intra-
day and inter-day. In this the present developed method, shown the good accuracy and 
precision. Accuracy ranges from 99.2% to100.3 % with the precision 3.57% to 5.34% in 
intra-day method. In inter-day method the accuracy ranges from 99.5% to 100.08%   
with the precision 5.78% to 6.31%.  Finally the data obtained here, was found to be 
within limits as per ICH guidelines and method was accurate. 
Intra-day studies: In this plasma concentration 100-800 ng/ml were injected six times 
and mean peak area was calculated separately for each concentration and from that 
accuracy and precision percentage RSD values were calculated and shown in table
(Table 7)
Table 7: Accuracy and precision studies of escitalopram oxalate (Intraday)
Sl.no
Conc. of       
drug (ng/ml)
Mean peak
Area*
Accuracy
(%)
RSD
(%)
1. 200 199526 99.2 4.98
2 400 312919 100.3 3.57
3 600 429303 99.9 5.32
*Average of six determinations.
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Inter-day studies: In this the plasma concentrations  of 100-800 ng/ml were injected 
into HPLC six times in three different days and mean peak areas were calculated and 
from that accuracy and precision  percentage RSD were calculated and shown in table 
(Table 8 ). The percentage relative standard deviation of precision for Escitalopram 
oxalate was less than 15% for the bioanalytical study. The results obtained were within 
limits.
Acceptance criteria: The percentage RSD value should be less than 15% for 
bioanalytical study.
Table 8:  Accuracy and precision studies of escitalopram oxalate (Interday)
Sl.no
Conc. of       
drug (ng/ml)
Mean peak
Area*
Accuracy
(%)
RSD
(%)
1 200 191206 99.6 5.78
2 400 336188 99.2 6.31
3 600 419568 100.08 6.11
*Average of three determinations.
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b) Linearity and range:
This method proved to be linear between ng/ml of Escitalopram oxalate in 
human plasma, with a typical calibration curve of correlation equation y = 0.06x +
0.216, correlation coefficient > 0.999 shown in table (Table 9 )
Table 9:  Calibration standards peak area
Concentration (ng/ml) Peak area of drug Peak area of IS Response factor
0 0
106856
0
100 123953 1.160
200 196849 1.847
400 308814 2.913
600 434903 4.078
800 546034 5.221
The chromatograms of the plasma calibration standards with concentrations 
100,200,400,600 and 800ng/ml were recorded and shown in figures (Fig 14) and their peak 
areas of both drug and internal standard were noted. The calibration curve for Escitalopram 
oxalate was plotted as peak response Vs concentration of the Escitalopram oxalate
calibration standards in plasma was shown ( Fig : 15-19 ).
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Fig 14 - Calibration curve for escitalopram oxalate
As we were using internal standard peak response was calculated for 
calibration curve. Peak response is the ratio of internal standard peak area to drug peak 
area. The correlation coefficient of escitalopram oxalate shown was 0.995 which was 
within limits. This calibration curve plotted was linear and showed that the method had 
adequate sensitivity to the concentration ( 100-800ng/ml) of the drug. Finally the data 
obtained, in this was within limits. Coefficient of correlation of Escitalopram oxalate
was found to be less than 0.99.
Acceptance criteria: The correlation coefficient should not less than 0.99
y = 0.0064x + 0.216
R² = 0.9956
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Fig 15- Chromatogram of IS and Escitalopram oxalate in human plasma100ng/ml
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Fig 16- Chromatogram of  IS and Escitalopram oxalate in human plasma 
200ng/ml
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Fig 17- Chromatogram of  IS and Escitalopram oxalate in human 
plasma400ng/ml
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Fig 18- Chromatogram of  IS and Escitalopram oxalate in human plasma 
600ng/ml
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Fig 19- Chromatogram of  IS and Escitalopram oxalate in human plasma 
800ng/ml
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c) Lower Limit of Quantification and Limit of Detection:
The LOD is the smallest concentration of the analyte which shows a measurable 
response. The LLOQ is the smallest concentration of the analyte, which shows response 
that can be accurately quantified and LLOQ = 10 × D/S and LOD = 3.3× D/S where, D is 
the standard deviation of y – intercepts of regression line and S is the slope of the 
calibration curve. This signal to noise ratio were performed by comparing measured signal 
of known low concentration of drug with those of blank plasma sample.
The Lower limit of quantification (LLOQ) and the Limit of Detection (LOD) for 
escitalopram oxalate were separately determined and reported, based on the calibration 
curve for spiked plasma solutions was found to be 23.79ng/ml and 7.3ng/ml respectively. 
d) Recovery from plasma:
A recovery study for escitalopram oxalate in plasma using acetonitrile was shown 
in table (Table 10). With concentrations 200ng/ml, 400ng/ml, 600ng/ml of escitalopram 
oxalate recovery was calculated and showed 100.2%, 99.4%, 100.4% relative recoveries 
and percentage RSD as 8.6%, 7.9% and 7.3% respectively. 
Acceptance criteria: For an assay method, mean recovery should be 85-105% ± 2%.
Table 10: Recovery studies of escitalopram oxalate
Levels
Conc. of drug 
added
(ng/ml)
Amt of drug recovered in 
plasma sample
(ng /ml)
Percentage
recovery
(%)
% RSD
I 200 200.08 100.04 4.2
II 400 401.5 100.3 6.8
III 600 598.9 99.75 5.9
**Average of six determinations.
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e) Ruggedness:
It expresses the precision within laboratories variations like different days, 
different analyst, and different equipments. Ruggedness of the method was assessed by 
spiking the plasma standard 6 times in two different days with different analyst and the 
standard solutions were analyzed by a different chemist and same instruments on a 
different day had been performed the reports were shown in table (Table 11 ).
The deviation among the results obtained by two chemists on a different day was 
well within the limits. Hence the method was rugged.
Acceptance criteria: The percentage RSD should be less than 15%.
Table 11:  Ruggedness studies for escitalopram oxalate
Drug
Concentration 
(ng/ml)
Mean peak 
area
%RSD
Day I  analyst – I
Escitalopram oxalate 200 195392 2.76
Day II  analyst – II
Escitalopram oxalate 200 199527 4.98
**Average of six determinations.
f) Specificity:
For specificity the peak purity studies were done. Here for escitalopram oxalate the 
peak purity index was 000 and the peak properties like peak profile were good for both 
standard and the sample. The peak purity and peak profiles for escitalopram oxalate
standard and sample were shown in figures (Fig 20-23) respectively. By the data obtained 
in this, the present method developed was specific as values were within limits.
Acceptance criteria: Purity angle should be less than purity threshold i.e.0.99-1.00
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Fig 20: Peak profile of standard escitalopram oxalate
Fig 21: Peak profile of escitalopram oxalate in human plasma
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Fig 22: Purity profile of escitalopram oxalate
Fig 23: Purity profile of escitalopram oxalate in human plasma
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g) System suitability:
These parameters were shown to be within specified limits. Column efficiency 
(theoretical plates), resolution factor and peak asymmetry factor, HETP, tailing factor, 
LLOQ are the system suitability parameters. These parameters of the optimized methods 
were found satisfactory. The results of the system suitability studies in plasma were shown 
in table (Table 12 ). These parameters were shown to be within specified limits.
Table 12: System Suitability Studies
Sl.no Parameters Escitalopram oxalate
1. Theoretical Plate 9533
2. Tailing Factor 0.995
3. HETP 15.77
4. LLOQ 23.79 ng/ml
5. LOD 7.3 ng/ml
6. Resolution 7.21
7. K 3.17
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8. SUMMARY AND CONCLUSION
A bio-analytical method was developed for the estimation of Escitalopram 
oxalate in human plasma by RP -HPLC method and was validated. Escitalopram is an 
antidepressant drug from the class called Selective Serotonin Reuptake Inhibitors 
(SSRI’s).The method was developed using 0.2% ortho phosphoric acid and acetonitrile 
in the ratio of 65:35% v/v. The peaks obtained for the drug of interest and internal 
standard by the present method were well resolved from each other without any 
interference and from the plasma endogenous proteins by Solid phase Extraction 
method (SPE method) and the peaks were symmetrical in nature with acceptable 
tailing factor.
All the analytical validation parameters were determined and found in the limit 
as per ICH guidelines, which indicates the validity of the method .The method was
validated with respect to specificity, linearity, accuracy, precision, ruggedness and 
robustness. The results of linearity, intraday and interday precision study and 
capability of the extraction method were within the limits of bioanalytical method 
development. The method was linear with a correlation coefficient of acceptable 
agreement, which is suitable for the estimation of Escitalopram oxalate in human 
plasma and other biological fluids.
The SPE method demonstrated relative recoveries with acceptable relative 
standard deviation. The lower limit of quantification (LLOQ) and limit of detection 
(LOD) for Escitalopram oxalate was found to be in nanograms. Hence the developed 
method is sensitive for the estimation of Escitalopram oxalate in trace amounts. The 
Peak purity studies showed that the peak purity index values were closer to unity 
hence reveals that the method developed was specific for the estimation of 
Escitalopram oxalate in blood and other biological fluids.
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From the current work it was finally concluded that the developed RP-HPLC 
method in human plasma using solid phase extraction for sample preparation by was 
found to be very simple, reliable, precise, accurate, sensitive and selective analytical 
method for the estimation of Escitalopram oxalate . The method is suitable for routine 
quantitative analysis in pharmaceutical dosage forms. The method developed can be 
used in therapeutic drug monitoring units, bioequivalence and bioavailability studies, 
pharmacokinetic and toxicology studies of Escitalopram oxalate.
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